fig3

Activation of the cGMP/protein kinase G system in breast cancer by the dopamine receptor-1

Figure 3. Characteristics of the cGMP/protein kinase G (PKG) pathway. Soluble guanylate cyclase (sGC) is activated by nitric oxide (NO) and by three drugs, namely Riociguate, YC-1, and Bay 41-2271, and is inhibited by ODQ. Activated sGC converts GTP to cGMP while phosphodiesterase 5 (PDE5) hydrolyzes cGMP to 5’GMP. PDE5 inhibitors include tadalafil (Cialis), sildenafil (Viagra) and vardenafil (Levitra). Elevated cGMP activates PKG, which affects many important targets

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/